Please login to the form below

Not currently logged in
Email:
Password:

Bayer sees increase in Q1 sales

Bayer has reported a five per cent increase in first-quarter sales of pharmaceuticals to €2.6bn compared to 2008, for products such as Betaferon and Nexavar

Bayer has reported a five per cent increase in first-quarter sales of pharmaceuticals to €2.6bn compared to 2008, for products such as Betaferon and Nexavar. Sales for the company's HealthCare unit gained three per cent to €3.8bn.

Betaferon/Betaseron posted a 9.9 per cent sales increase to €301m over the comparable quarter, while Nexavar's revenue jumped 36 per cent to €137m. The German pharmaceutical and chemical company also reported that combined quarterly revenue from contraceptives YAZ, Yasmin and Yasminelle increased 7.4 per cent to €319m.

CEO Werner Wenning said "our pharmaceutical business saw pleasing growth overall" and added that Bayer's HealthCare unit "plans to achieve currency-adjusted growth rates ahead of the market average in all divisions" in 2009.

However, overall company profit decreased 44 per cent to €425m due to the impact of the global economic recession on other business segments such as plastics and adhesive chemicals. Quarterly group revenue was 7.5 per cent lower than the same period last year at €7.9bn.

30th April 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Digitas Health

Digitas Health is the only digital-at-the-core brand agency designed to connect today's healthcare brands with today's healthcare consumers and professionals....

Latest intelligence

Where next in Alzheimer’s disease R&D?
How past failures and emerging biology are reshaping drug development...
Brain scan
Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...

Infographics